Drug
Ux003
Ux003: highest development phase Phase 3, developed by Ultragenyx Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| UX003 NCT02432144 | Phase 3 | Sly Syndrome |
| UX003 NCT01856218 | Phase 1/2 | Mucopolysaccharidosis Type 7 |
Latest
No recent events.
Follow Ux003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.